News

New KoolTemp GTS parcels have higher performance and lower cost and weight

Walgreens' Pharma Dynamics subsidiary will be merged into CareMetX

Pharma track-and-trace arrives, but will take years to be fully implemented; drug compounding also gets a new regulatory framework

Growth includes 1-4% CAGR in U.S., 0-3% in Europe and 14-17% in China. US specialties have a twist

Finance, marketing and other nontraditional users find value in the company's sales and inventory data

Nonprofit will continue industry collaborations on shared resources for drug discovery and development

HDMA members gather to discuss track-and-trace technicalities, even while Congress almost--again--passes the Drug Quality and Security Act

New "emergent biopharma" service combine compliance with pricing, market access

Will the Microsoft Surface tablet displace Apple's iPad popularity among pharma sales forces?

But their evidence validates, to a degree, industry's claim that coupons are not generics killers

Regulatory compliance remains the top concern globally, but security and spoilage are high in the Asia/Pacific region

New service launched by WEGO Health offers rapid feedback from key opinion influencers in consumer healthcare

Highly automated facility can process 50 million prescriptions annually for CVS Caremark's book of business

IAG Cargo's Heathrow facility is up and running; FedEx has begun construction of a facility at its Memphis hub

Schreiner MediPharm develops wrap-around labels for Sweden's SHL Medical

SK&A compiles a list: Kaiser tops in number of doctors, but Ascension Health leads in number of offices

Retailers, distributors and manufacturers are being affected by federal rules on durable medical equipment (DME)

Blue Cross/Blue Shield PBM says seven steps help manage costs

Exhibition brings out the latest in temperature-controlled shipping

Bill includes voluntary oversight by FDA of outsourced compounded pharmaceuticals, national distributor licensure, and a timetable for serialization and drug tracking

The Medicare Part D switchover of 2007 is only a partial proxy for what the healthcare system will experience in the next several years

Results of a survey panel by QPharma, presented at PDMA Sharing Conference, show a wide spread of reactions and concerns over agg-spend rules

UDIs will be in place starting in late 2014, and rolling out over the next four years thereafter

While FDA dithers on regulatory guidance, state efforts to anticipate biosimilar regulation are mostly being rejected